HDAC9 and CDH1-related diffuse gastric and lobular breast cancer syndrome: Using 2D and 3D preclinical models with distinct genetic backgrounds, we demonstrate the potential utility of HDAC inhibitors for the chemoprevention of HDGC and treatment of sporadic E-cadherin-deficient cancers.